Veru (VERU) Preferred Stock Liabilities (2019 - 2020)

Veru (VERU) posted quarterly Preferred Stock Liabilities of $2.7 million for Q1 2020, up 203.56% quarter-over-quarter from $899000.0 in Q3 2019.

Veru (VERU) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends

Veru (VERU) has reported Preferred Stock Liabilities for 2 consecutive years, with $2.7 million the latest figure, recorded in Q1 2020.

In Q1 2020, Preferred Stock Liabilities changed N/A year-over-year to $2.7 million; the TTM figure through Mar 2020 stood at $2.7 million (changed N/A YoY), while the FY2019 annual figure was $899000.0, changed N/A from the prior year.
Preferred Stock Liabilities grew to $2.7 million in Q1 2020 per VERU's latest filing, from $899000.0 in the prior quarter.
Across five years, Preferred Stock Liabilities topped out at $2.7 million in Q1 2020 and bottomed at $899000.0 in Q3 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Veru	60.85 Mn	35.06 Mn	-	-

Download Data

Date	Value
Mar 31, 2020	2.73 Mn
Sep 30, 2019	899,000.00